VIERNES 27 DE FEBRERO

15:30-15:40  Bienvenida
             XXXXXXXXXXX

15:40-16:00  Abstracts sobre sitagliptina
             Dr. Esteban Jódar Gimeno

16:00-16:15  Conferencia introductoria
             Domenico Accili  The new biology of diabetes Oral Presentation #1336
             Dr. Manel Puig Domingo

16:15-17:45  Módulo 1. Sesiones plenarias
             Moderador: Dr. Manuel Muñoz Torres

                     Dr. Alberto Moreno Carazo
                     ADA Diabetes Care Symposium—New Drug Therapies, Innovative
                     Management Strategies, and Novel Drug Targets

                     Dr. Elías Delgado Álvarez
                     Michael Berger debate: Metformin: where is the evidence?

                     Dr. Javier Escalada San Martín
                     Hot topics in diabetes

                     Dra. Noemí González Pérez de Villar
                     ACC/AHA Guidelines for Lipids Appropriate for Diabetes?

                     Dra. Sharona Azriel Mira
                     Frontiers in Inpatient Diabetes Management

17:45-18:15  Café

18:15-19:45  Módulo 2. Epidemiología, genética, obesidad y otros factores de riesgo
             Moderador: Dr. José M.ª Hernández i Anguera

                     Dr. Alberto Moreno Carazo
                     381-OR president oral session LDL-cholesterol Is Not a Good Marker of
                     Cardiovascular Risk in Type 1 Diabetes: Observational Study in 30,778
                     Patients—A Report from the National Diabetes Register in Sweden
                     CHRISTEL HERO
95-OR Central Insulin Administration Improves Whole-Body Insulin Sensitivity via Hypothalamus and Parasympathetic Outputs in Men

MARTIN HENI

Dr. Elías Delgado Álvarez
Intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery (GLUCO-CABG Trial)

196 Insulin pumps (CSII) and cardiovascular diseases and mortality in the Swedish national diabetes register S. Gudbjørnsdottir

Dr. Javier Escalada San Martín
Oral Presentation #45 Impact of diabetes mellitus on long-term prognosis in patients with preserved heart failure: a report from the Swedish Heart Failure Registry (S-HFR) ISABELLE JOHANSSON

Oral Presentation #245 Cancer occurrence in type 1 diabetes patients: a 4-country study with 8800 cancer cases in 3.7 mio person-years BENDIX CARSTENSEN

Dra. Noemí González Pérez de Villar
AT-0969: Type2 Diabetes, Autoimmunity and Coronary Atherosclerosis Jayanta Chakraborty

P448 Mean plasma volume in t2 DM: Is there a relationship between mean platelet volumna and diabetic microvascular complications Cadirci K /P379 Mean platelet volume reflects framingham risk score in intermediate hyperglycemia Kim S

Dra. Sharona Azriel Mira
Oral presentation 32. Global Assessment of Factors Associated with Target Glycemic Control in Youth with Type 1 Diabetes (T1D): The TEENs Study. LORI M. LAFFEL

Oral presentation 338: m Prediction of first cardiovascular disease event in type 1 diabetes. The Steno T1 risk engine. D. VISTISEN

21:30 Cena
SÁBADO 28 DE FEBRERO

09:30-11:00  Módulo 3. Clínica y tratamiento (I)
Moderador: Dr. Pedro Mezquita Raya

Dr. Alberto Moreno Carazo
332-OR Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/ Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
127-OR Reduced Hypoglycemia Risk with an Inhaled Insulin Compared to Injected Prandial Insulin in Type 1 Diabetes BRUCE W. BODE /128-or Efficacy and Safety Evaluation of Technosphere® Insulin vs. Inhaled Placebo in Insulin-Naïve Type 2 Diabetes JULIO ROSENSTOCK

Dr. Elías Delgado Álvarez
148 Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL in people with type 1 diabetes (EDITION 4) P.D. Home

932 Pharmacokinetic (PK) and pharmacodynamic (PD) properties of BioChaperone Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes (T1DM) U. Hoevelmann

Dr. Javier Escalada San Martín
Oral Presentation #181 Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk factors in overweight/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial. Bruce Bode

ePoster #803 LX4211, a dual inhibitor of SGLT1/SGLT2, reduces postprandial glucose in patients with type 2 diabetes mellitus and moderate to severe renal impairment. PABLO LAPUERTA

Dra. Noemí González Pérez de Villar
MON-0991: Bariatric Surgery and Diabetes: Implications of Type 1 Versus Insulin Requiring Type 2 Spyridoula Maraka

OR 40-5 Improved Oral Glucose Tolerance in Prediabetics and Type 2 Diabetics (T2D) in a Pilot Clinical Trial Testing a Novel Gastrointestinal (GI) Microbiome Modulator Mark Louis Heiman
Dra. Sharona Azriel Mira
Oral presentation 66: Impact of BMI on HbA1c reduction, hypoglycemia rates and insulin requirements in response to IDegLira in patients with type 2 diabetes (T2D). J.B. BUSE

Oral presentation 156: TTP054, a Novel, Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Lowers HbA1c in Subjects with Type 2 Diabetes Mellitus (T2DM). STEPHANIE GUSTAVSON / 155-OR TTP273, an Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Notably Reduces Glycemia in Subjects with Type 2 Diabètes Mellitus (T2DM) STEPHANIE GUSTAVSON.

11:30-13:00 Módulo 4. Clínica y tratamiento (II)
Moderador: Dr. Francisco Tinahones Madueño

Dr. Alberto Moreno Carazo
99-OR Lorcaserin (LOR) Can Improve Weight Loss (WL) in Patients (Pts) with Prediabetes and Reduce Progression to Diabetes in Obese and Overweight Patients RICHARD W. NESTO/2039-P Lorcaserin (lor) Free Plasma Levels at Recommended Dose Are Sufficient to Activate 5-HT2c but Not 2a or 2b Receptors ERIC RAVUSSIN

169-OR Biomarkers Associated with Severe Hypoglycemia and Failure to Achieve Good Glycemic Control in T2DM: The ACCORD Study LISA CHOW

Dr. Elías Delgado Álvarez
4 Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs saxagliptin or dapagliflozin add-on alone in poorly controlled type 2 diabetes on metformin L. Hansen

38 Efficacy and safety of once weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) F. Giorgino

Dr. Javier Escalada San Martín
Oral Presentation #111 The INITIATOR study: real-world treatment patterns and outcomes in patients with type 2 diabetes initiating insulin glargine or liraglutide. PHILIP LEVIN

ePoster #999 Efficacy and safety of insulin pump therapy in type 2 diabetes: the OpT2mise study. Yves Reznik
Dra. Noemí González Pérez de Villar
SAT-0971: Long-Term Effect of Dipeptidyl Peptidase-IV Inhibitors on Cardiovascular Events in Type 2 Diabetes Mellitus Middle-Age Patients: A Meta-Analysis
Samir Patel1 / OR34-6: Dipeptidyl Peptidase-4 Inhibitors Do Not Increase the Risk of Cardiovascular Events in Type 2 Diabetes: A Population-Based Cohort Study
Seoyoung C. Kim

OR26-4: Liraglutide As Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus: A Randomized Clinical Trial
Nitesh D Kuhadiya1

Dra. Sharona Azriel Mira
Oral presentation 288: Long-term Efficacy and Safety of Canagliflozin (CANA) in Older Patients with Type 2 Diabetes Mellitus (T2DM) Over 104 Weeks. BRUCE BODE,
Oral presentation 388: Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes (T1D) Complicated by Severe Hypoglycemia. BERNHARD J. HERING,

13:00-13:15 Conferencia de cierre
Treatment of Type 2 Diabetes—New and Not-So-New Ideas
Dra. Rebeca Reyes

13:15 Cierre de la sesión

13:45 Cocktail y despedida